Literature DB >> 24321837

Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience.

M V Fogaça1, F M C V Reis2, A C Campos3, F S Guimarães4.   

Abstract

The prelimbic medial prefrontal cortex (PL) is an important encephalic structure involved in the expression of emotional states. In a previous study, intra-PL injection of cannabidiol (CBD), a major non-psychotomimetic cannabinoid present in the Cannabis sativa plant, reduced the expression of fear conditioning response. Although its mechanism remains unclear, CBD can facilitate 5HT1A receptor-mediated neurotransmission when injected into several brain structures. This study was aimed at verifying if intra-PL CBD could also induce anxiolytic-like effect in a conceptually distinct animal model, the elevated plus maze (EPM). We also verified if CBD effects in the EPM and contextual fear conditioning test (CFC) depend on 5HT1A receptors and previous stressful experience. CBD induced opposite effects in the CFC and EPM, being anxiolytic and anxiogenic, respectively. Both responses were prevented by WAY100,635, a 5HT1A receptor antagonist. In animals that had been previously (24h) submitted to a stressful event (2h-restraint) CBD caused an anxiolytic, rather than anxiogenic, effect in the EPM. This anxiolytic response was abolished by previous injection of metyrapone, a glucocorticoid synthesis blocker. Moreover, restraint stress increased 5HT1A receptors expression in the dorsal raphe nucleus, an effect that was attenuated by injection of metyrapone before the restraint procedure. Taken together, these results suggest that CBD modulation of anxiety in the PL depend on 5HT1A-mediated neurotransmission and previous stressful experience.
© 2013 Published by Elsevier B.V. and ECNP.

Entities:  

Keywords:  5HT(1A) receptors; Anxiety; Cannabidiol; Glucocorticoids; Prefrontal cortex; Stress

Mesh:

Substances:

Year:  2013        PMID: 24321837     DOI: 10.1016/j.euroneuro.2013.10.012

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  41 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors.

Authors:  Hanna J Szkudlarek; Sagar J Desai; Justine Renard; Brian Pereira; Christopher Norris; Christina E L Jobson; Nagalingam Rajakumar; Brian L Allman; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

3.  Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Authors:  Erin M Rock; Cheryl L Limebeer; Gavin N Petrie; Lauren A Williams; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

4.  A time-dependent contribution of hippocampal CB1 , CB2 and PPARγ receptors to cannabidiol-induced disruption of fear memory consolidation.

Authors:  Ana Maria Raymundi; Thiago R da Silva; Aleksander R Zampronio; Francisco S Guimarães; Leandro J Bertoglio; Cristina A J Stern
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

Review 5.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

6.  Involvement of M1 and CB₁ receptors in the anxiogenic-like effects induced by neostigmine injected into the rat prelimbic medial prefrontal cortex.

Authors:  M V Fogaça; A G Fedoce; N C Ferreira-Junior; F S Guimarães; L B Resstel
Journal:  Psychopharmacology (Berl)       Date:  2016-02-13       Impact factor: 4.530

7.  Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).

Authors:  Brian D Klein; Catherine A Jacobson; Cameron S Metcalf; Misty D Smith; Karen S Wilcox; Aidan J Hampson; John H Kehne
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

8.  Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Authors:  Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2018-03-22       Impact factor: 7.853

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 10.  Medial prefrontal cortex in neurological diseases.

Authors:  Pan Xu; Ai Chen; Yipeng Li; Xuezhi Xing; Hui Lu
Journal:  Physiol Genomics       Date:  2019-08-02       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.